Key Highlights
- Ondine Biomedical (LSE: OBI) develops Steriwave, a light-activated nasal decolonisation treatment used to reduce surgical-site infections.
- Full-year 2025 revenue rose 29% to C$2.6m, with Steriwave in use at 37 hospitals and surgical clinics across seven countries.
- A pending US Phase 3 trial readout and a cash runway extending only to early Q4 2026 are the central near-term issues for the business.
A light-activated infection-prevention technology
Ondine Biomedical Inc. (LSE: OBI) is an unusual proposition on London's junior market: a Vancouver-based medical-technology company whose shares trade as depositary interests (CDIs), a mechanism that lets a foreign-incorporated firm list on AIM. Its core product, Steriwave, is a nasal decolonisation treatment that uses photodisinfection — a light-activated antimicrobial process — to kill bacteria in the nose before surgery, aiming to reduce surgical-site infections.
Ondine closed at 13p on 3 August 2026, down about 1.9% on the day, for a market value of roughly £73m. Over the past year the stock has ranged between 7.5p and 18.5p, so the current 13p sits roughly in the middle of that band.
A small but growing commercial base
Full-year revenue for 2025, reported on 4 June 2026, rose 29% to C$2.6m (from C$2.0m in 2024) — real growth, but from a very low base and far short of covering costs. Steriwave was in use at 37 hospitals and surgical clinics by the year-end, up about 28% on a year earlier, across Canada, the UK, Switzerland, Germany, Spain, Mexico and Australia.
That footprint demonstrates genuine clinical interest, but the pace of adoption remains the central question. Hospital procurement is slow, budget-constrained and evidence-driven, and converting pilots into recurring orders takes time.
Clinical evidence is accumulating
During 2025 and early 2026 the company reported supportive studies: an intensive-care study it said showed a 39.5% reduction in pneumonia (14 April 2026), and data from the University of Ottawa Heart Institute pointing to a 'marked reduction' in surgical-site infections (23 April 2026).
Individual hospital studies and top-line summaries are not the same as a large, randomised, peer-reviewed trial, and results announced via regulatory filings should be treated as the company's own presentation of the data, pending full publication.
The US regulatory prize — and the wait
The potential game-changer is the United States. Ondine has completed enrolment in its Phase 3 pivotal study — branded LANTERN — recruiting 5,188 patients across 14 US hospitals and four Canadian centres. Success would underpin a New Drug Application to the US Food and Drug Administration.
In its FY2025 results the company said top-line results were 'expected by the end of Spring 2026'. As of the time of writing no such results had been announced, so this remains a pending catalyst. Binary trial read-outs are, by their nature, high-risk: any timing expectation is management's own guidance, not a guarantee.
Funding risk is the near-term issue
Ondine's operating loss widened to C$30m in 2025 (from C$19.4m), and it used C$23.8m of cash in operations over the year. Cash stood at just C$10.6m at 31 December 2025. In April 2026 the company raised about £5m (C$9.23m) at 12p a share, issuing roughly 41.7 million new shares.
Management said that raise was expected to extend the cash runway only 'through to early Q4 2026'. With the fourth quarter now imminent, the arithmetic points to a further fundraising — or a transformational LANTERN result — being needed before long.






Please wait processing your request...